IRS1 and Insulin resistance: The results suggest that therapeuticintervention aimed at addressing the interaction between MG53 and insulinreceptor substrate 1 (IRS-1) can be developed, which could serve as a novelstrategy for treating insulin resistance-linked metabolic conditions [79].